Frank I Lin
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Frank I Lin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06479811 · [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersNational Cancer Institute (NCI) · recruiting · Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma · principal investigator
- Ph1/Ph2NCT06427798 · Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand TherapyNational Cancer Institute (NCI) · recruiting · Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma · principal investigator
- Ph1/Ph2NCT04086485 · Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)National Cancer Institute (NCI) · recruiting · Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms · principal investigator
- Ph2NCT03206060 · Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaNational Cancer Institute (NCI) · recruiting · Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 49 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Improving PSMA-based radioligand therapy via combination radioligand therapyZIABC011895 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $150,585 awarded in 2025Same name and institution; not confirmed by an ID
- Pb212 VMT alpha NET in treatment and re-treatment of SSTR+ tumorsZIABC012138 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 to 2025 · $301,170 awarded in 2025Same name and institution; not confirmed by an ID
- Phase 1-2 study of Lu177-DOTATATE and olaparib in neuroendocrine tumorsZIABC011827 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2025 · $75,293 awarded in 2025Same name and institution; not confirmed by an ID
- Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoaZIABC011789 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2017 to 2025 · $150,585 awarded in 2025Same name and institution; not confirmed by an ID
- Protection of Salivary Gland in PSMA-targeted radioligand therapyZIABC011826 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2025 · $75,293 awarded in 2025Same name and institution; not confirmed by an ID
- Th227-mesothelin and Zr89-mesothelin antibody conjugate in mesothelin tumorsZIABC011825 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2022 · $85,931 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in neuroblastoma.